The Claim
In mouse models of chemotherapy-induced senescence, co-administration of apigenin with mitoxantrone reduces tumor growth by 74.9% compared to placebo, primarily through suppression of SASP-driven chemoresistance in stromal cells without direct effects on cancer cells.
What the research says
Supports is higher
Support is ahead, but a single strong opposing study can change this.
These are independent scores, not a percentage. Higher-grade studies count more, so a single strong opposing study can outweigh several weaker ones.
In mice treated with chemotherapy, adding apigenin to mitoxantrone reduces tumor growth by 74.9% compared to no additional treatment, by blocking signals from surrounding cells that make the cancer resistant to the drug.
See the scientific wording
In mouse models of chemotherapy-induced senescence, apigenin co-administration with mitoxantrone reduces tumor growth by 74.9% compared to placebo, primarily by suppressing SASP-driven chemoresistance in stromal cells rather than directly affecting cancer cells.
Apigenin binds to a protein called PRDX6 in support cells near tumors, blocking its ability to release a fatty acid that triggers inflammation. This stops a chain reaction involving other proteins that would normally turn short-term stress signals into long-term inflammatory signals. Without these inflammatory signals, the tumor cells become vulnerable again to chemotherapy, causing the tumor to shrink dramatically.
What the research says
1 studyIn mice, when apigenin is given with chemo, it helps the treatment shrink tumors much more by calming down the inflammatory signals from nearby support cells—not by killing cancer cells directly. This makes the chemo work better.
Score breakdown, mechanism chain, raw evidence, ideal studies needed & 1 supporting studies
Not medical advice. For informational purposes only. Always consult a qualified healthcare professional before making health decisions.